Wockhardt寻求DGGI批准在印度260千亩市场注射阿斯巴胰岛素。 Wockhardt seeks DCGI approval for its Aspart insulin injection in India's ₹260-crore market.

一家设在孟买的制药公司Wockhardt已寻求印度药品总经理批准其快速反应的胰岛素模拟物Aspart注射。 Wockhardt, a Mumbai-based pharmaceutical company, has sought approval from India's Drug Controller General for its fast-acting insulin analog, Aspart injection. 这个产品是Wockhardt糖尿病治疗组合的一部分, 目标是市场价值超过260千瓦, 竞争有限。 This product, part of Wockhardt's diabetes treatment portfolio, targets a market valued at over ₹260 crore with limited competition. 该公司还计划开发更多的胰岛素类别和GLP-1激动剂. The company also aims to develop more insulin analogs and GLP-1 agonists. 最近,Wockhardt的股份在申请后上升了4.3%,反映了投资者的信心。 Recently, Wockhardt’s shares rose 4.3% following the application, reflecting investor confidence.